

STEMLINE THERAPEUTICS INC  
Form 8-K  
March 24, 2017

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **March 23, 2017**

**Stemline Therapeutics, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-35619**  
(Commission File Number)

**45-0522567**  
(IRS Employer Identification No.)

**750 Lexington Avenue**  
**Eleventh Floor**  
**New York, New York 10022**

Edgar Filing: STEMLINE THERAPEUTICS INC - Form 8-K

(Address of Principal Executive Offices)

**(646) 502-2311**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communications pursuant to Rule 425 under the Securities Act.
  
  - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
  
  - o Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
  
  - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
-

**Item 8.01 Other Events.**

On March 23, 2017, Stemline Therapeutics, Inc. announced completion of enrollment of the Stage 3 cohort of the SL-401 pivotal trial in blastic plasmacytoid dendritic cell neoplasm (BPDCN).

A copy of such press release is being furnished as Exhibit 99.1 to this report.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

The following exhibit is furnished herewith:

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press release issued by Stemline Therapeutics, Inc., dated March 23, 2017.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 24, 2017

**Stemline Therapeutics, Inc.**  
(Registrant)

By

/s/ Kenneth Hoberman  
Kenneth Hoberman  
Chief Operating Officer

**INDEX TO EXHIBITS**

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press release issued by Stemline Therapeutics, Inc., dated March 23, 2017.